IMiDs can alter substrate specificity of CRBN to a number of endogenous cellular targets, redirecting its activity on the recruitment and degradation of novel selected substrates via proteasome, such as IKZF1 and IKZF3, crucial transcription factors (TFs) for MM cell survival17–19. The gene discussed is IKZF1; the disease is Miyoshi myopathy.